Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 2 N=345 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 2 N=208 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Phase 2 N=64 Study of Tremelimumab in Patients With Advanced Solid Tumors
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Phase 1 N=32 Pazopanib and ARQ 197 for Advanced Solid Tumors
Solid Tumor
Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events
Phase 1 N=14 Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) — 288.55; 105.8 μg·h/L/mg
Phase 2 N=1,131 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
Phase 1 N=57 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Phase 2 N=57 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Phase 2 N=140 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Advanced Rare Tumours
Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants
Phase 1 N=21 Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Phase 2 N=109 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors · Lung Cancer · Breast Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 — 4; 4; 10; 12 Participants
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Phase 1 N=98 Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID
Phase 2 N=95 XTX202 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only) — 0; 0; 0; 1 Participants
Phase 2 N=20 Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Skin Squamous Cell Carcinoma · Appendix Adenocarcinoma · Rare Lesion
Primary: Overall Response Rate (ORR) — 2 Participants
Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Phase 1 N=62 Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Advanced Solid Tumor
Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 1 N=20 GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Phase 2 N=252 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
Phase 1 N=477 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Solid Tumor
Primary: Overall Response Rate (ORR) — 4.3; 20.0; 0.0; 30.4 Percentage of Participants
Phase 1 N=26 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 1 N=191 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Solid Tumor
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 59; 20; 21; 21 Participants